Standigm is a company that develops an artificial intelligence (AI) platform for drug development. It was established in 2015 by Jinhan Kim, Sang Ok Song, and So Jeong Yun. It has received funding from investors such as Mirae Asset Venture Investment, Kakao Ventures, and LB Investment. The company is headquartered in Seoul, South Korea.
Standigm's AI platform, called Standigm BEST, allows pharmaceutical companies to generate novel drug compounds or chemical analogs. Its drug discovery latent space allows its clients to design compounds at the molecular level. It is possible to determine the final compound structure based on the pre-determined novel seed molecule or chemical analog property.
Standigm Insight is intended to complement their clients' in-house drug discovery process to predict compound activity in the early phase of development, alongside indication prediction, pathway and therapeutic pattern, and target prioritization in the later phases.